Novartis Buys Chinook For $3.5 Billion In Race To Treat Rare Kidney Disease
By Ludwig Burger (Reuters) -Novartis said it has agreed to acquire U.S. biotech firm Chinook Therapeutics for up to $3.5 billion to boost its late-stage drug development line-up, raising the stakes in the race for a rare kidney disease treatment. Seattle-based Chinook’s shareholders will receive $3.2 billion, or $40 per share, in cash under the…
